You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMebendazole
Accession NumberDB00643  (APRD01086)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]
Structure
Thumb
Synonyms
(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
MBDZ
Mebendazol
Mebendazol
Mébendazole
Mebendazolum
Vermox
External Identifiers
  • R 17635
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vermox Tablets 100 mgtablet100 mgoralJanssen Inc1982-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Emvermtablet, chewable100 mg/1oralAmedra Pharmaceuticals LLC2016-02-15Not applicableUs
Mebendazoletablet, chewable100 mg/1oralPhysicians Total Care, Inc.1996-04-04Not applicableUs
Mebendazoletablet, chewable100 mg/1oralbryant ranch prepack2010-04-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LomperEsteve
MeberixAversi
MebexCipla
MebezolJohnson
MebfilFourrts Laboratories
MebutarAndromaco
MebzolJulphar
MendazoleGlaxoSmithKline
MezoleYuan Chou
MinyoozoleEmil
MopenLi Taka Pharmaceuticals
MultielminOsorio de Moraes
NecaminAché
OvexMcNeil
PanamoxJayson
PantelminJanssen
TesicalSintesina
ThelmoxRemedica
TicoquerRoot
VermoxBiotech
Brand mixturesNot Available
SaltsNot Available
Categories
UNII81G6I5V05I
CAS number31431-39-7
WeightAverage: 295.2927
Monoisotopic: 295.095691297
Chemical FormulaC16H13N3O3
InChI KeyInChIKey=OPXLLQIJSORQAM-UHFFFAOYSA-N
InChI
InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
IUPAC Name
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
SMILES
COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Benzimidazole
  • Acetophenone
  • Aryl ketone
  • Benzoyl
  • Aminoimidazole
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.
PharmacodynamicsMebendazole is a (synthetic) broad-spectrum anthelmintic. The principal mode of action for Mebendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.
Mechanism of actionMebendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.
Related Articles
AbsorptionPoorly absorbed (approximately 5 to 10%) from gastrointestinal tract. Fatty food increases absorption.
Volume of distributionNot Available
Protein binding90-95%
Metabolism

Primarily hepatic. Primary metabolite is 2-amino-5-benzoylbenzimidazole, but also metabolized to inactive hydroxy and hydroxyamino metabolites. All metabolites are devoid of anthelmintic activity.

SubstrateEnzymesProduct
Mebendazole
Not Available
2-amino-5-benzoylbenzimidazoleDetails
Route of eliminationIn man, approximately 2% of administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite.
Half life2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).
ClearanceNot Available
ToxicityAcute oral toxicity (LD50): 620 mg/kg [Mouse]. Symptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching.
Affected organisms
  • Helminthic Microorganisms
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.9261
Caco-2 permeable+0.7261
P-glycoprotein substrateNon-substrate0.6073
P-glycoprotein inhibitor IInhibitor0.5844
P-glycoprotein inhibitor IIInhibitor0.7534
Renal organic cation transporterNon-inhibitor0.8464
CYP450 2C9 substrateNon-substrate0.749
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6532
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6779
Ames testAMES toxic0.7212
CarcinogenicityNon-carcinogens0.9102
BiodegradationNot ready biodegradable0.994
Rat acute toxicity2.5855 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9515
hERG inhibition (predictor II)Non-inhibitor0.8028
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Teva pharmaceuticals usa
  • Mcneil pediatrics
Packagers
Dosage forms
FormRouteStrength
Tablet, chewableoral100 mg/1
Tabletoral100 mg
Prices
Unit descriptionCostUnit
Mebendazole 100 mg Chew Tabs16.42USD tab
Mebendazole 100 mg tablet chew5.32USD tablet
Mebendazole powder5.03USD g
Vermox 100 mg Chewable Tablet4.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point288.5 °CPhysProp
water solubility71.3 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.83SANGSTER (1994)
logS-3.88ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0387 mg/mLALOGPS
logP2.95ALOGPS
logP3.26ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)8.44ChemAxon
pKa (Strongest Basic)3.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.08 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity81.5 m3·mol-1ChemAxon
Polarizability31.1 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 3,657,267.

General References
  1. Link [Link]
External Links
ATC CodesP02CA51P02CA01
AHFS Codes
  • 08:08.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.8 KB)
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Mebendazole.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Mebendazole.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mebendazole.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Mebendazole.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Mebendazole.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Mebendazole.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Mebendazole.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Mebendazole.
AmiodaroneThe metabolism of Mebendazole can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Mebendazole.
AmodiaquineThe serum concentration of Mebendazole can be decreased when it is combined with Amodiaquine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Mebendazole.
AprepitantThe serum concentration of Mebendazole can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Mebendazole.
AtazanavirThe metabolism of Mebendazole can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Mebendazole.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Mebendazole.
AtomoxetineThe metabolism of Mebendazole can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Mebendazole.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Mebendazole.
BevacizumabBevacizumab may increase the cardiotoxic activities of Mebendazole.
BexaroteneThe serum concentration of Mebendazole can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Mebendazole can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Mebendazole.
BortezomibThe metabolism of Mebendazole can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mebendazole can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mebendazole.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mebendazole.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Mebendazole.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Mebendazole.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mebendazole.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Mebendazole.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Mebendazole.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Mebendazole.
CarbamazepineThe serum concentration of Mebendazole can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Mebendazole.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Mebendazole.
CeritinibThe serum concentration of Mebendazole can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Mebendazole.
ChloroquineThe serum concentration of Mebendazole can be decreased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Mebendazole.
CimetidineThe serum concentration of Mebendazole can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Mebendazole.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Mebendazole.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Mebendazole.
ClarithromycinThe metabolism of Mebendazole can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Mebendazole.
ClemastineThe metabolism of Mebendazole can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Mebendazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Mebendazole.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Mebendazole.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Mebendazole.
ClotrimazoleThe metabolism of Mebendazole can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Mebendazole.
CobicistatThe metabolism of Mebendazole can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Mebendazole.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Mebendazole.
ConivaptanThe serum concentration of Mebendazole can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mebendazole.
CrizotinibThe metabolism of Mebendazole can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Mebendazole.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mebendazole.
CyclosporineThe metabolism of Mebendazole can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Mebendazole.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Mebendazole.
DabrafenibThe serum concentration of Mebendazole can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Mebendazole.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Mebendazole.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Mebendazole.
DarunavirThe metabolism of Mebendazole can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Mebendazole can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Mebendazole.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Mebendazole.
DeferasiroxThe serum concentration of Mebendazole can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Mebendazole can be decreased when combined with Delavirdine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mebendazole.
DexamethasoneThe serum concentration of Mebendazole can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Mebendazole.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Mebendazole.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mebendazole.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mebendazole.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Mebendazole.
DigoxinDigoxin may decrease the cardiotoxic activities of Mebendazole.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mebendazole.
DihydroergotamineThe metabolism of Mebendazole can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Mebendazole.
DiltiazemThe metabolism of Mebendazole can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Mebendazole.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Mebendazole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Mebendazole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mebendazole.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Mebendazole.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mebendazole.
DoxycyclineThe metabolism of Mebendazole can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Mebendazole can be decreased when combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Mebendazole.
EfavirenzThe serum concentration of Mebendazole can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Mebendazole.
EnzalutamideThe serum concentration of Mebendazole can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Mebendazole.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Mebendazole.
ErythromycinThe metabolism of Mebendazole can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Mebendazole.
Eslicarbazepine acetateThe serum concentration of Mebendazole can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Mebendazole.
EstriolThe serum concentration of Estriol can be increased when it is combined with Mebendazole.
EstroneThe serum concentration of Estrone can be increased when it is combined with Mebendazole.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mebendazole.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Mebendazole.
EtravirineThe serum concentration of Mebendazole can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Mebendazole.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Mebendazole.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Mebendazole.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Mebendazole.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Mebendazole.
FluconazoleThe metabolism of Mebendazole can be decreased when combined with Fluconazole.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Mebendazole.
FluvoxamineThe metabolism of Mebendazole can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Mebendazole can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Mebendazole can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Mebendazole can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Mebendazole can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Mebendazole.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Mebendazole.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Mebendazole.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Mebendazole.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Mebendazole.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Mebendazole.
HydroxychloroquineThe serum concentration of Mebendazole can be decreased when it is combined with Hydroxychloroquine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Mebendazole.
IdelalisibThe serum concentration of Mebendazole can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Mebendazole can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Mebendazole.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Mebendazole.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Mebendazole.
IndinavirThe metabolism of Mebendazole can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Mebendazole.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Mebendazole.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Mebendazole.
IsavuconazoniumThe metabolism of Mebendazole can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Mebendazole can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Mebendazole can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Mebendazole can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Mebendazole.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Mebendazole.
KetoconazoleThe metabolism of Mebendazole can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Mebendazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Mebendazole.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Mebendazole.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Mebendazole.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Mebendazole.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Mebendazole.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Mebendazole.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Mebendazole.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Mebendazole.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Mebendazole.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Mebendazole.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Mebendazole.
LopinavirThe metabolism of Mebendazole can be decreased when combined with Lopinavir.
LosartanThe serum concentration of Losartan can be increased when it is combined with Mebendazole.
LovastatinThe metabolism of Mebendazole can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Mebendazole can be increased when it is combined with Luliconazole.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Mebendazole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mebendazole.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Mebendazole.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Mebendazole.
MetronidazoleThe risk or severity of adverse effects can be increased when Mebendazole is combined with Metronidazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Mebendazole.
MifepristoneThe metabolism of Mebendazole can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Mebendazole.
MitotaneThe serum concentration of Mebendazole can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Mebendazole.
ModafinilThe serum concentration of Mebendazole can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Mebendazole.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mebendazole.
NadololThe serum concentration of Nadolol can be increased when it is combined with Mebendazole.
NafcillinThe serum concentration of Mebendazole can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mebendazole.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Mebendazole.
NefazodoneThe metabolism of Mebendazole can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Mebendazole can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Mebendazole.
NetupitantThe serum concentration of Mebendazole can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Mebendazole can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Mebendazole.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Mebendazole.
NilotinibThe metabolism of Mebendazole can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Mebendazole.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Mebendazole.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Mebendazole.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Mebendazole.
OlaparibThe metabolism of Mebendazole can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Mebendazole.
OsimertinibThe serum concentration of Mebendazole can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Mebendazole.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Mebendazole.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mebendazole.
PalbociclibThe serum concentration of Mebendazole can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Mebendazole.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Mebendazole.
PentobarbitalThe metabolism of Mebendazole can be increased when combined with Pentobarbital.
PhenobarbitalThe metabolism of Mebendazole can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Mebendazole.
PhenytoinThe serum concentration of Mebendazole can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Mebendazole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Mebendazole.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Mebendazole.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Mebendazole.
PosaconazoleThe metabolism of Mebendazole can be decreased when combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Mebendazole.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Mebendazole.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Mebendazole.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Mebendazole.
PrimaquineThe serum concentration of Mebendazole can be decreased when it is combined with Primaquine.
PrimidoneThe metabolism of Mebendazole can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Mebendazole.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Mebendazole.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Mebendazole.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Mebendazole.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Mebendazole.
QuinineThe serum concentration of Quinine can be increased when it is combined with Mebendazole.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Mebendazole.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Mebendazole.
RanolazineThe metabolism of Mebendazole can be decreased when combined with Ranolazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Mebendazole.
RifabutinThe metabolism of Mebendazole can be increased when combined with Rifabutin.
RifampicinThe metabolism of Mebendazole can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Mebendazole.
RifapentineThe metabolism of Mebendazole can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mebendazole.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Mebendazole.
RitonavirThe metabolism of Mebendazole can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Mebendazole.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Mebendazole.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Mebendazole.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Mebendazole.
SaquinavirThe metabolism of Mebendazole can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Mebendazole.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Mebendazole.
SildenafilThe metabolism of Mebendazole can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mebendazole.
SiltuximabThe serum concentration of Mebendazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mebendazole can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Mebendazole.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Mebendazole.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Mebendazole.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Mebendazole.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Mebendazole.
St. John's WortThe serum concentration of Mebendazole can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Mebendazole can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Mebendazole can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Mebendazole.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Mebendazole.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Mebendazole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Mebendazole.
TelaprevirThe metabolism of Mebendazole can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Mebendazole.
TelithromycinThe metabolism of Mebendazole can be decreased when combined with Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Mebendazole.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Mebendazole.
TiclopidineThe metabolism of Mebendazole can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Mebendazole.
TocilizumabThe serum concentration of Mebendazole can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Mebendazole.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Mebendazole.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Mebendazole.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mebendazole.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Mebendazole.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Mebendazole.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Mebendazole.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Mebendazole.
VenlafaxineThe metabolism of Mebendazole can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Mebendazole.
VerapamilThe metabolism of Mebendazole can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Mebendazole.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Mebendazole.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Mebendazole.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Mebendazole.
VoriconazoleThe metabolism of Mebendazole can be decreased when combined with Voriconazole.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Mebendazole.
ZiprasidoneThe metabolism of Mebendazole can be decreased when combined with Ziprasidone.
Food Interactions
  • Lipid rich meals may improve absorption.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural molecule activity
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBA1A
Uniprot ID:
Q71U36
Molecular Weight:
50135.25 Da
References
  1. Lubega GW, Geary TG, Klein RD, Prichard RK: Expression of cloned beta-tubulin genes of Haemonchus contortus in Escherichia coli: interaction of recombinant beta-tubulin with native tubulin and mebendazole. Mol Biochem Parasitol. 1993 Dec;62(2):281-92. [PubMed:8139621 ]
  2. MacDonald LM, Armson A, Thompson AR, Reynoldson JA: Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol Biochem Parasitol. 2004 Nov;138(1):89-96. [PubMed:15500920 ]
  3. Oxberry ME, Gear TG, Prichard RK: Assessment of benzimidazole binding to individual recombinant tubulin isotypes from Haemonchus contortus. Parasitology. 2001 Jun;122(Pt 6):683-7. [PubMed:11444621 ]
  4. Ochola DO, Prichard RK, Lubega GW: Classical ligands bind tubulin of trypanosomes and inhibit their growth in vitro. J Parasitol. 2002 Jun;88(3):600-4. [PubMed:12099434 ]
  5. Wampande EM, Richard McIntosh J, Lubega GW: Classical ligands interact with native and recombinant tubulin from Onchocerca volvulus with similar rank order of magnitude. Protein Expr Purif. 2007 Oct;55(2):236-45. Epub 2007 Apr 25. [PubMed:17662615 ]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Unfolded protein binding
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBB4B
Uniprot ID:
P68371
Molecular Weight:
49830.72 Da
References
  1. Lubega GW, Geary TG, Klein RD, Prichard RK: Expression of cloned beta-tubulin genes of Haemonchus contortus in Escherichia coli: interaction of recombinant beta-tubulin with native tubulin and mebendazole. Mol Biochem Parasitol. 1993 Dec;62(2):281-92. [PubMed:8139621 ]
  2. MacDonald LM, Armson A, Thompson AR, Reynoldson JA: Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol Biochem Parasitol. 2004 Nov;138(1):89-96. [PubMed:15500920 ]
  3. Oxberry ME, Gear TG, Prichard RK: Assessment of benzimidazole binding to individual recombinant tubulin isotypes from Haemonchus contortus. Parasitology. 2001 Jun;122(Pt 6):683-7. [PubMed:11444621 ]
  4. Ochola DO, Prichard RK, Lubega GW: Classical ligands bind tubulin of trypanosomes and inhibit their growth in vitro. J Parasitol. 2002 Jun;88(3):600-4. [PubMed:12099434 ]
  5. Wampande EM, Richard McIntosh J, Lubega GW: Classical ligands interact with native and recombinant tubulin from Onchocerca volvulus with similar rank order of magnitude. Protein Expr Purif. 2007 Oct;55(2):236-45. Epub 2007 Apr 25. [PubMed:17662615 ]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23